Emerging targets for prostate adenocarcinoma therapy: How molecular biology may drive towards a more tailored approach?

Current Drug Targets

Volumn 17, Issue 3, 2016, Pages 266-275

  Ambrosio, Maria Raffaella ^a   Pirtoli, Luigi ^b   del Vecchio, Maria Teresa ^b  

^a Department of Medical Biotechnology ^*  (Italy)

^b UNIVERSITY OF SIENA   (Italy)

Author keywords

Gleason score; Immunotherapy; Monoclonal antibody; Prognostic factors; Prostate adenocarcinoma; Target therapy

Indexed keywords

ABIRATERONE ACETATE; APALUTAMIDE; AZD3514; BAFILOMYCIN; CABAZITAXEL; CFG 920; CIXUTUMUMAB; DOCETAXEL; DUTASTERIDE; ENZALUTAMIDE; EPI 001; ERLOTINIB; EVEROLIMUS; EZN 4176; FIGITUMUMAB; GALETERONE; IPILIMUMAB; METYRAPONE; NIRAPARIB; OLAPARIB; ONCI I3B; ORTERONEL; PREDNISONE; RILIMOGENE GALVACIREPVEC; RUCAPARIB; SIPULEUCEL T; TOREMIFENE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VELIPARIB; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ARTICLE; AUTOCRINE EFFECT; CLINICAL TRIAL (TOPIC); CUSHING SYNDROME; DRUG TARGETING; GENE DOSAGE; GENE MUTATION; HUMAN; MOLECULAR BIOLOGY; MULTICENTER STUDY (TOPIC); PARACRINE SIGNALING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE ADENOCARCINOMA; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; STEROIDOGENESIS; GENETICS; MALE; MOLECULARLY TARGETED THERAPY; PATHOLOGY; PERSONALIZED MEDICINE; PROGNOSIS; PROSTATIC NEOPLASMS;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CLINICAL TRIALS AS TOPIC; HUMANS; MALE; MOLECULAR TARGETED THERAPY; PRECISION MEDICINE; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 84961134205     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450116666151019102220     Document Type: Article

References (88)

1. Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. Eur Urol 2012; 61(6): 1079-92.
2. Danza G, Di Serio C, Rosati F, et al. Notch signaling modulates hypoxia-induced neuroendocrine differentiation of human prostate cancer cells. Mol Cancer Res 2012; 10(2): 230-8.
3. Miller AM, Pisa P. Tumor escape mechanisms in prostate cancer. Cancer Immunol Immunother 2007; 56(1): 81-7.
4. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. AUA Prostate Cancer Clinical Guideline Update Panel. J Urol 2007; 177(6): 2106-31.
5. Nouri M, Ratther E, Stylianou N, et al. Androgen-targeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: an opportunity for interven- tion. Front Oncol 2014; 4: 370.
6. Ottman R, Nguyen C, Lorch R, et al. MicroRNA expressions associated with progression of prostate cancer cells to anti-androgen therapy resistance. Mol Cancer 2014; 13: 1.
7. Beltran H, Rubin MA. New strategies in prostate cancer: translating genomics into the clinic. Clin Cancer Res 2013; 19(3): 517-23.
8. Mazaris E, Tsiotras A. Molecular pathways in prostate cancer. Nephrourol Mon 2013; 5(3): 792-800.
9. Liu HH, Tsai YS, Lai CL, et al. Evolving personalized therapy for castration-resistant prostate cancer. Biomedicine (Taipei) 2014; 4: 2.
10. Karayi MK, Markham AF. Molecular biology of prostate cancer. Prostate Cancer Prostatic Dis 2004; 7(1): 6-20.
11. Hsing AW. Hormones and prostate cancer: what’s next? Epidemiol Rev 2001; 23: 42-58.
12. Lee D. High androgen receptor levels are predictive of decreased survival in prostate cancer. Clin Prostate Cancer 2003; 2: 13-14.
13. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004; 25(2): 276-308.
14. Tan ME, Li J, Xu HE, Melcher K, Yong E. Androgen recep-tor: structure, role in prostate cancer and drug discovery. Acta Pharmacol Sin 2015; 36(1): 3-23.
15. Karantanos T, Evans CP, Tombal B, Thompson TC, Montironi R, Isaacs WB. Understanding the mechanisms of androgen depriva- tion resistance in prostate cancer at the molecular level. Eur Urol 2015; 67(3): 470-9.
16. Oudard S. Progress in emerging therapies for advanced prostate cancer. Cancer Treat Rev 2013; 39(3): 275-89.
17. Yu Z, Cai C, Gao S, et al. Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor. Clin Cancer Res 2014; 20(15): 4075-85.
18. Gomez L, Kovac JR, Lamb DJ. CYP17A1 inhibitors in castration-resistant prostate cancer. Steroids 2015; 95: 80-7.
19. Ivachtchenko AV, Mitkin OD, Kudan EV, et al. Preclinical development of ONC1-13B, novel antiandrogen for prostate cancer treatment. J Cancer 2014; 5(2): 133-42.
20. Loddick SA, Ross SJ, Thomason AG, et al. AZD3514: a small molecule that modulates androgen receptor signaling and function in vitro and in vivo. Mol Cancer Ther 2013; 12(9): 1715-27.
21. Agarwal N, Di Lorenzo G, Sonpavde G, et al. New agents for prostate cancer. Ann Oncol 2014; 25(9): 1700-9.
22. Patel JC, Maughan BL, Agarwal AM, et al. Emerging molecularly targeted therapies in castration refractory prostate cancer. Prostate Cancer 2013; 2013: 981684.
23. Mostaghel EA. Beyond T. DHT-novel steroid derivatives capable of wild type androgen receptor activation. Int J Biol Sci 2014; 10(6): 602-13.
24. Lee JT, Lehmann BD, Terrian DM, et al. Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle 2008; 7(12): 1745-62.
25. Antonarakis ES, Carducci MA, Eisenberger MA. Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett 2010; 29: 1-13.
26. Duran I, Montagut C, Calvo E, et al. Overcoming docetaxe resistance in advanced castration-resistant prostate cancer (CRPC): a phase I/II trial of the combination of temsirolimus and docetaxel. J Clin Oncol 2012; 30: 5.
27. Courtney KD, Manola JB, Elfiky AA, et al. A Phase I Study of everolimus and docetaxel in patients with castration-resistant prostate cancer. Clin Genitourin Cancer 2014: 13(2): 113-23.
28. Gururajan M, Posadas EM, Chung LW. Future perspectives of prostate cancer therapy. Transl Androl Urol 2012; 1(1): 19-32.
29. Anai A, Goodison S, Shiverick K, et al. Knock-down of Bcl-2 by antisense oligodeoxynucleotidesinduces radiosensitization and inhibition of angiogenesisin human PC-3 prostate tumor xenografts. Mol Cancer Ther 2007; 6: 101-11.
30. Higano CS. Potential use of custirsen to treat prostate cancer. Onco Targets Ther 2013; 6: 785-97.
31. Rocca BJ, Ginori A, Barone A, et al. Translationally controlled tumor protein in prostatic adenocarcinoma: correlation with tumor grading and endocrine treatment-related changes. Biomed Res Int 2015: 985950.
32. Acunzo J, Baylot V, So A. TCTP as therapeutic target in cancers. Cancer Treat Rev 2014; 40(6): 760-9.
33. Baylot V, Katsogiannou M, Andrieu C, et al. Targeting TCTP as a new therapeutic strategy in castration-resistant prostate cancer. Mol Ther 2012; 20(12): 2244-56.
34. Pu H, Horbinski C, Hensley PJ, et al. PARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesis. Carcinogenesis 2014; 35(11): 2592-601.
35. Rajan P, Stockley J, Sudbery IM, et al. Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre-and post-treatment prostatic biopsies from patients with advanced prostate cancer. BMC Cancer 2014; 14: 977.
36. Li L, Chang W, Yang G, et al. Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer. Sci Signal 2014; 7(326): ra47.
37. Hussain M, Carducci MA, Slovin S, et al. Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer. Invest New Drugs 2014; 32(5): 904-12.
38. Stadler WM, Cao D, Vogelzang NJ, et al. A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer. Clin Cancer Res 2004; 10: 3365-70.
39. Sooriakumaran P, Coley HM, Fox SB, et al. A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer. Anticancer Res 2009; 29: 1483-8.
40. Brawer MK, Deering RE, Brown M, et al. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer 1994; 73: 678-87.
41. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005; 69: 11-6.
42. Bilusic M, Wong YN. Anti-angiogenesis in prostate cancer: knocked down but not out. Asian J Androl 2014; 16(3): 372-7.
43. Tannock IF, Fizazi K, Ivanov S, et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol 2013; 14(8): 760-8.
44. Fiorio PA, Brossa A, Bernardini M, et al. Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib. BMC Cancer 2014; 14: 939.
45. Sonpavde G, Periman PO, Bernold D, et al. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol 2010; 21: 319-24.
46. Suzman DL, Antonarakis ES. Castration-resistant prostate cancer: latest evidence and therapeutic implications. Ther Adv Med Oncol 2014; 6(4): 167-79.
47. Dahut WL, Madan RA, Karakunnel JJ, et al. Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU Int 2013; 111(8): 1269-80.
48. Sridhar SS, Joshua AM, Gregg R, et al. A Phase II study of GW786034 (pazopanib) with or without bicalutamide in patients with castration-resistant prostate cancer. Clin Genitourin Cancer 2014; 13(2): 124-9.
49. Ambrosio MR, Rocca BJ, Barone A, et al. Lymphatic vascularization in prostate adenocarcinoma: correlation with tumour grade, androgen withdrawal and prognosis. Anticancer Res 2015; 35(10): 5595-5600.
50. Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003; 4: 915-25.
51. Van Leenders GJ, Sookhlall R, Teubel WJ, et al. Activation of c-MET induces a stem-like phenotype in human prostate cancer. PLoS One 2011; 6: e26753.
52. Nishida S, Hirohashi Y, Torigoe T, et al. Expression of hepatocyte growth factor in prostate cancer may indicate a biochemical recurrence after radical prostatectomy. Anticancer Res 2015; 35(1): 413-8.
53. Adamo V, Noto L, Franchina T, et al. Emerging targeted therapies for castration-resistant prostate cancer. Front Endocrinol (Lausanne) 2012; 3: 73.
54. Dai Y, Siemann DW. Constitutively active c-Met kinase in PC-3 cells is autocrine-independent and can be blocked by the Met kinase inhibitor BMS-777607. BMC Cancer 2012; 12: 198.
55. Ryan CJ, Rosenthal M, Ng S, et al. Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res 2013; 19(1): 215-24.
56. Smith MR, Sweeney CJ, Corn PG, et al. Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study. J Clin Oncol 2014; 32(30): 3391-9.
57. Zheng Y, Basel D, Chow SO, et al. Targeting IL-6 and RANKL signaling inhibits prostate cancer growth in bone. Clin Exp Metastasis 2014; 31(8): 921-33.
58. Goc A, Al-Husein B, Katsanevas K, et al. Targeting Src-mediated Tyr216 phosphorylation and activation of GSK-3 in prostate cancer cells inhibit prostate cancer progression in vitro and in vivo. Oncotarget 2014; 5(3): 775-87.
59. Phillips R. Prostate cancer: Dasatinib fails to improve on docetaxel for metastatic CRPC. Nat Rev Urol 2014; 11(1): 5.
60. Nelson JB, Udan MS, Guruli G, et al. Endothelin-1 inhibits apoptosis in prostate cancer. Neoplasia 2005; 7(7): 631-7.
61. Younis IR, George DJ, McManus TJ, et al. Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer. Cancer Chemother Pharmacol 2014; 73(5): 991-7.
62. Taneja SS. Re: Denosumab and bone metastasis-free survival in men with non-metastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Urol 2014; 192(2): 421-2.
63. Parker C, Sartor O. Radium-223 in prostate cancer. N Engl J Med 2013; 369(17): 1659-60.
64. Gururajan M, Posadas EM, Chung LWK. Future perspectives of prostate cancer therapy. Transl Androl Urol 2012; 1(1): 19-32.
65. Overall CM, López-Otín C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer 2002; 2(9): 657-72.
66. Ahmad S, Sweeney P, Sullivan GC, et al. DNA vaccination for prostate cancer, from preclinical to clinical trials-where we stand? Genet Vaccines Ther 2012; 10(1): 9.
67. Fernández-García EM, Vera-Badillo FE, Perez-Valderrama B, et al. Immunotherapy in prostate cancer: review of the current evidence. Clin Transl Oncol 2014; 17(5): 339-57.
68. Campbell CT, Gulley JL, Oyelaran O, et al. Humoral response to a viral glycan correlates with survival on PROSTVAC-VF. Proc Natl Acad Sci USA 2014; 111(17): E1749-58.
69. Kittai A, Meshikhes M, Aragon-Ching JB. Ipilimumab: a potential immunologic agent in the treatment of metastatic castration- resistant prostate cancer. Cancer Biol Ther 2014; 15(10): 1299-300.
70. Lorente D, Mateo J, Zafeiriou Z, et al. Switching and withdrawing hormonal agents for castration-resistant prostate cancer. Nat Rev Urol 2015; 12(1): 37-47.
71. van Soest RJ, de Morrée ES, Kweldam CF, et al. Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration-resistant prostate cancer. Eur Urol 2015; 67(6): 981-5.
72. National Comprehensive Cancer Network-Prostate Cancer NCCN clinical practice guidelines in oncology- Version 2 2014 NCCN.org.
73. Spratt DE, Pei X, Yamada J, Kollmeier MA, Cox B, Zelelwski MJ. Long term survival and toxicity in patients treated with high dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2013; 85: 686-92.
74. Alberti C. Prostate cancer: radioresistance molecular target-related markers and foreseeable modality of radiosensitization. Eur Rev Med Pharmaco Sci 2014; 18: 2275-82.
75. Chang L, Graham PH, Hao J, et al. PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathway. Cell Death Dis 2014; 5: e1437.
76. Vlachostergios PJ, Papandreou CN. Targeting neuroendocrine prostate cancer: molecular and clinical perspectives. Front Oncol 2015; 5: 6.
77. Beltran H, Rickman DS, Park K, et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011; 1(6): 487-95.
78. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004; 113(6): 913-23.
79. Naldi I, Taranta M, Gherardini L, et al. Novel epigenetic target therapy for prostate cancer: a preclinical study. PLoS One 2014; 9(5): e98101.
80. Takayama KI, Suzuki T, Tsutsumi S, et al. RUNX1, an androgen-and EZH2-regulated gene, has differential roles in AR-dependent and -independent prostate cancer. Oncotarget 2015; 10; 6(4).
81. Jung K, Reszka R, Kamlage B, et al. Tissue metabolite profiling identifies differentiating and prognostic biomarkers for prostate carcinoma. Int J Cancer 2013; 133(12): 2914-24.
82. Huang C, Freter C. Lipid metabolism, apoptosis and cancer therapy. Int J Mol Sci 2015; 16(1): 924-49.
83. Ambrosio MR, Piccaluga PP, Ponzoni M, et al. The alteration of lipid metabolism in Burkitt lymphoma identifies a novel marker: adipophilin. PLoS One 2012; 7(8): e44315.
84. Schlaepfer IR, Glodé LM, Hitz CA, et al. Inhibition of lipid oxidation increases glucose metabolism and enhances 2-deoxy-2-[18f]fluoro-d-glucose uptake in prostate cancer mouse xenografts. Mol Imaging Biol 2015; 17(4): 529-38.
85. Danza G, Di Serio C, Ambrosio MR, et al. Notch3 is activated by chronic hypoxia and contributes to the progression of human prostate cancer. Int J Cancer 2013; 133(11): 2577-86.
86. Schmidt SM, Schag K, Müller MR, et al. Induction of adipophilin-specific cytotoxic t lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis. Cancer Res 2004; 64: 1164-70.
87. Maqungo M, Kaur M, Kwofie SK. DDPC: Dragon database of genes associated with prostate cancer. Nucl Acids Res 2011; 39: D980-5.
88. Derleth CL, Yu EY. Targeted therapy in the treatment of castration-resistant prostate cancer. Oncology 2013; 27(7): 620-8.